Eli Lilly and Insilico Medicine forge $2.75bn AI-driven R&D pact
Eli Lilly is joining forces with artificial intelligence (AI)-powered biotech, Insilico Medicine, in a drug discovery and development…
Ozempic Goes Generic —But Not in the US
A drug that helped turn Novo Nordisk into Europe’s most valuable company is about to lose its…
FDA approves high-dose Wegovy shots
Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help…
2 Top AI Healthcare Stocks to Buy and Hold
Many of the top companies successfully cashing in on artificial intelligence (AI) are in the technology sector. However,…
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
March 2 (Reuters) – Eli Lilly CFO ‌Lucas Montarce said ‌on Monday it is ​preparing to launch its…
1 Reason Why I’d Hold This Weight‑Loss Drug Leader Through Any Market Crash
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are locked in a battle around GLP-1 weight-loss drugs.…
NHS must keep medicine rebate down or lose investment
Wednesday 18 February 2026 2:27 pm  |  Updated: Wednesday 18 February 2026 3:10 pm Share Facebook Share on Facebook…
JPMorgan builds $2.93 billion stake in health care stock
JPMorgan Chase just planted a massive $2.93 billion flag in perhaps one of the hottest corners of the…
The most controversial Super Bowl ad of 2025 is back for more
Super Bowl Sunday is the holy grail of advertising thanks to its massive viewership, with an average of…
Hims and Hers Health’s compounded Wegovy pill offering fuels market jitters
Feb 5 (Reuters) – Hims & Hers said it would begin offering compounded versions of Novo Nordisk’s Wegovy…
Hims and Hers Health’s compounded Wegovy pill offering fuels market jitters
Feb 5 (Reuters) – Hims & Hers said it would begin offering compounded versions of Novo Nordisk’s Wegovy…
How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q4 Results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…